KISQALI is used in women with a type of breast cancer called hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that is locally advanced or has spread to other parts of the body (metastatic). It is used in combination with an aromatase inhibitor or fulvestrant, which are used as hormonal anticancer therapies.

Women who have not reached menopause will also be treated with a medicine called a luteinising hormone releasing hormone (LHRH) agonist.

More information

Summary of product characteristics (SPC) for KISQALI

This link will take you to the electronic medicines compendium (emc) website, which is a non-Novartis website.

Patient information leaflet (PIL) for KISQALI

This link will take you to the electronic medicines compendium (emc) website, which is a non-Novartis website.

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See yellowcard.mhra.gov.uk for how to report side effects.

HCP20-C022 July 2020.
×

Ask Speakers

×

Medical Information Request

Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You should also report side effects directly via the Yellow Card Scheme at yellowcard.mhra.gov.uk.
By reporting side effects you can help provide more information on the safety of this medicine.